leadf
logo-loader
AIM:AVCT

Avacta Group PLC

Receive alerts
Market:
AIM
Market Cap:
£563.96 m
Price
223.93 GBX
Change
3.19%
52 weeks high
230.00
52 weeks low
12.62

In brief

At Avacta we have developed Affimer technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets.

Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.